MS Drugs Show Greater Differences in Relapse Rates Than Disability Outcomes, Real-World Study Finds
Source Summary
A real-world study found that multiple sclerosis patients treated with B-cell-depleting drugs or high-efficacy therapies experienced lower relapse rates and fewer brain lesions compared to those on oral medications. However, at the 2-year mark, disability outcomes did not differ significantly between treatment groups.
Why it matters
This finding suggests that while certain MS drugs reduce clinical markers of disease activity, these improvements may not translate to measurable differences in long-term disability progression within a 2-year period.
